Obesity Management - a Clinician’s Perspective
Obesity management
Abstract
The global epidemic of obesity has affected almost every country in the world, causing an enormous social and health burden. Although many counter-measures have been introduced against this epidemic, obesity is still on the rise. An important step in this area was made when obesity was classified as a disease. The recognition of obesity as a disease enables governments and state agencies to develop their own plans to curb the obesity epidemic. Obesity has been recognized as a problem from ancient times, and different measures have been suggested as solutions. Modern management of obesity is currently based on the following therapeutic principles: diet, exercise, psychological support, pharmacological treatment, and bariatric surgery. The history of pharmaceutical treatment is rather long and full of withdrawals of the drugs due to various reasons. New perspectives and promising results were introduced with a class of drugs based on incretins. These drugs were developed as agonists of gastrointestinal peptides in a mono form or a combination of two or three different agonists, achieving results similar to the effects of bariatric surgery. Currently, about 70 different therapeutical principles are in the process of development. Problems related to the drugs on the market are their high prices, limited capacity for production, and lack of experience regarding long-term use.
References
Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B, et al. SURMOUNT-1 Investigators. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022;387(3):205-216.
Duncan I, Kerr D, Aggarwal R, Huynh N, et alet al. New drugs for obesity, is the excitement affordable? Population Health Manag 2023;26(5):356-357.
Gargantilla Madera P, Arroyo Pardo N. Hasday: tratamiento de la obesidad en el siglo x. Endocrinol Nutr. 2016;63:100-101.
Bray GA, Heisel WE, Afshin A, Jensen MD, Dietz WH, Long M, et al. The Science of Obesity Management: An Endocrine Society Scientific Statement. Endocr Rev. 2018;39(2):79-132.
Quarta C, Claret M, Zeltser LM, Williams KW, Yeo GSH, Tschöp MH, . POMC neuronal heterogeneity in energy balance and beyond: an integrated view. Nat Metab. 2021 Mar;3(3):299-308.
Müller TD, Blüher M, Tschöp MH, DiMarchi RD. Anti-obesity drug discovery: advances and challenges. Nat Reviews Drug Discov. 2022;21(3):201-223.
Gutt S, Schraier S, Gonz S, GBagnes MF, Yu M, González CD, Di Girolamo G. Long-term pharmacotherapy of obesity in patients that have undergone bariatric surgery: pharmacological prevention and management of body weight regain. Expert Opin Pharmacother. 2019;20(8):939-947.
Wing RR, Phelan S. Long-term weight loss maintenance. Am J Clin Nutr. 2005;82(1 Suppl):222S-225S.
Gupta H. Barriers to and Facilitators of Long Term Weight Loss Maintenance in Adult UK People: A Thematic Analysis. Int J Prev Med. 2014;5(12):1512-20.
Melby CL, Paris HL, Foright RM, Peth J. Attenuating the Biologic Drive for Weight Regain Following Weight Loss: Must What Goes Down Always Go Back Up? Nutrients. 2017;9(5):468.
Grzelka K, Wilhelms H, Dodt S, Dreisow ML, Madara JC, Walker SJ, et al. A synaptic amplifier of hunger for regaining body weight in the hypothalamus. Cell Metab. 2023;35(5):770-785.e5.
Furigo IC, Teixeira PDS, de Souza GO, Couto GCL, Romero GG, Perelló M, et al. Growth hormone regulates neuroendocrine responses to weight loss via AgRP neurons. Nat Commun. 2019;10(1):662.
van Baak MA, Mariman ECM. Mechanisms of weight regain after weight loss - the role of adipose tissue. Nat Rev Endocrinol. 2019;15(5):274-287.
van Baak, MA, Mariman, ECM. Obesity-induced and weight-loss-induced physiological factors affecting weight regain. Nat Rev Endocrinol. 2023;19(11):655–670.
Garvey T. Is obesity or adiposity-based chronic disease curable: the set point theory, the environment, and second-generation medications. Endocr Pract. 2022;28(2):214-222.
Yurista S, Eder R, Feeley M, Kodur N, Tang WHW, Nguyen CT. A Closer Look at ACC/AHA and ESC Guidelines for Managing Obesity and Overweight in Adults. JACC Adv. 2023;2(7):100570.
Bloch MJ. The dietary approaches to stop hypertension (DASH) diet-promise unmet. J Am Soc Hypert. 2017;11(6):323–324.
Richardson LA, Izuora K, Basu A. Mediterranean diet and its association with cardiovascular disease risk factors: A scoping review. Int. J Environ Res Public Health. 2022;19(19):12762.
Tettamanzi F, Bagnardi V, Louca P, Nogal A, Monti GS, Mambrini SP, et al. A high protein diet is more effective in improving insulin resistance and glycemic variability compared to a mediterranean diet—a cross-over controlled in patient dietary study. Nutrients. 2021;13(12):4380.
Chao A, Quigley KM, Wadden T. Dietary interventions for obesity: clinical and mechanistic findings. J Clin Invest. 2021;131(1):e140065.
Wiechert M, Holzapfel C. Nutrition Concepts for the Treatment of Obesity in Adults. Nutrients. 2022;14(1):169.
Oppert JM, Bellicha A, van Baak M, Battista F, Beaulieu K, Blundell JE, et al. Exercise training in the management of overweight and obesity in adults: Synthesis of the evidence and recommendations from the European Association for the Study of Obesity Physical Activity Working Group. Obes Rev. 2021;22(S4):e13273.
Gjermeni, E, Kirstein AS, Kolbig F, Kirchhof M, Bundalian L, Katzmann JL, et al. Obesity-An Update on the Basic Pathophysiology and Review of Recent Therapeutic Advances. Biomolecules. 2021;11(10):1426.
Brandfon S, Eylon A, Khanna D, Parmar MS. Advances in Anti-obesity Pharmacotherapy: Current Treatments, Emerging Therapies, and Challenges. Cureus. 2023;15(10):e46623.
Chakhtoura M, Haber R, Ghezzawi, Rhayem C, Tcheroyan R, Mantzorosc C. Pharmacotherapy of obesity: an update on the available medications and drugs under investigation. eClinicalMedicine. 2023;58:101882.
Kosmalski M, Deska K, BK, B, RB, R K, BK, Besk M, Pietras T. Pharmacological Support for the Treatment of Obesity-Present and Future. Healthcare (Basel). 2023 Feb 2;11(3):433.
Onakpoya IJ, Lee JJ, Mahtani KR, Aronson JK, Heneghan CJ. Naltrexone-bupropion (Mysimba) in management of obesity: A systematic review and meta-analysis of unpublished clinical study reports. Br J Clin Pharmacol. 2020;86(4):646-667.
Thomas B, Lindblad AJ, Luu T, Paige A. Naltrexone-bupropion for weight loss. Can Fam Physician. 2023;69(9):627.
Drucker DJ. GLP-1 physiology informs the pharmacotherapy of obesity. Mol Metab. 2022 Mar;57:101351.
Le Roux CW, Astrup A, Fujioka K, Greenway F, Lau DCW, Van Gaal L, et al. SCALE Obesity Prediabetes NN8022-1839 Study Group. 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial. Lancet. 2017;389(10077):1399-1409.
Lundgren JR, Janus C, Jensen SBK, Juhl CR, Olsen LM, Christensen RM, et al. Healthy weight loss maintenance with exercise, liraglutide, or both combined. N Engl J Med. 2021;384(18):1719-1730.
Mozaffarian D. GLP-1 Agonists for Obesity—A New Recipe for Success? JAMA. 2024 Mar 26;331(12):1007-1008.
Melson E, Ashraf U, Papamargaritis D, Davies MJ. What is the pipeline for future medications for obesity? Int J Obes (Lond). 2024 Feb 1. doi: 10.1038/s41366-024-01473-y. Epub ahead of print.
Naeem M, Imran L, Banatwala UESS. Unleashing the power of retatrutide: A possible triumph over obesity and overweight: A correspondence. Health Sci Rep. 2024 Feb 5;7(2):e1864.
Roomy MA, Hussain K, Behbehani HM, Abu-Farha J, Al-Harris R, Ambi AM, et al. Therapeutic advances in obesity management: an overview of the therapeutic interventions. Front Endocrinol (Lausanne). 2024 Apr 23;15:1364503.
Busetto L, Bettini S, Makaronidis J, Roberts CA, Halford JCG, Batterham RL. Mechanisms of weight regain. Eur J Intern Med. 2021;93:3-7.
Lucas E, Simmons O, Tchang B, Aronne L. Pharmacologic management of weight regain following bariatric surgery. Front Endocrinol. 2023;13:1043595.
